BRCA2 and PTEN hamartoma tumor syndrome: These rates are intermediate between those reported in BRCA1 carriers (57% high grade, 85% TN) and BRCA2 carriers (56% high grade, 23% TN) [41], suggesting differences in tumor biology between PHTS and BRCA-associated breast cancers.